Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diffuse Large B Cell Lymphoma Lymphoma | Drug: Pembrolizumab | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 29 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Study of Pembrolizumab for PD-L1 Gene-Altered, Relapsed/Refractory DLBCL |
Actual Study Start Date : | September 4, 2019 |
Estimated Primary Completion Date : | August 20, 2022 |
Estimated Study Completion Date : | August 20, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Pembrolizumab Treatment |
Drug: Pembrolizumab
Subjects will receive pembrolizumab treatment at a dose of 200mg IV every 3 weeks for a duration of 2 years (35 cycles).
Other Name: Keytruda
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Male/female participants who are at least 18 years of age on the day of signing informed consent with a histologically confirmed diagnosis of DLBCL will be enrolled in this study.
Note: Patients with high-grade B cell lymphomas not otherwised specified and those with MYC and BCL2 translocations (double hit lymphoma) are eligible, as are patients with transformed indolent lymphoma, so long as PD-L1 gene alterations are present.
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
C.) patient must have negative pregnancy test within 72 hours of beginning treatment if WOCBP
Participants must have received ≥ 2 lines of prior systemic therapy, ≥ 1 line of prior systemic therapy (if ineligible for or refused autologous stem cell transplantation), or have received 1 line of prior therapy with primary-refractory disease or have relapsed within 12 months from the time of initial diagnosis.
Note: patients having undergone prior CAR T cell therapy are eligible, as are patients having received a prior allogeneic transplantation, provided they do not meet any of the exclusionary GVHD criteria, and are at least 5 years removed from the date of their transplant.
Have adequate organ function within 10 days prior to the date of treatment allocation. Please see below for Adequate Organ Function Laboratory Values:
Hematological
Renal
Hepatic
Coagulation
Exclusion Criteria:
Has received chemotherapy, monoclonal antibody therapy, or targeted small molecule therapy within 4 weeks prior to the first dose of study medication. Subjects must have recovered (≤ Grade 1) from adverse events related to a previously administered agent (patients with ≤ Grade 2 neuropathy are eligible). Subjects who have previously received CAR T cell therapy are eligible provided that relapse occurred > 90 days following the date of CAR T cell infusion.
Note: If a participant received major surgery, he or she must have recovered adequately from complications from the intervention prior to starting study treatment.
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded
Contact: Justin Kline, MD | 773-702-5550 | jkline@medicine.bsd.uchicago.edu |
United States, Illinois | |
The University of Chicago Medicine | Recruiting |
Chicago, Illinois, United States, 60637 | |
Contact: Justin Kline, MD 773-702-5550 jkline@medicine.bsd.uchicago.edu | |
Principal Investigator: Justine Kline, MD |
Principal Investigator: | Justin Kline, MD | University of Chicago |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | June 17, 2019 | ||||
First Posted Date ICMJE | June 19, 2019 | ||||
Last Update Posted Date | January 7, 2021 | ||||
Actual Study Start Date ICMJE | September 4, 2019 | ||||
Estimated Primary Completion Date | August 20, 2022 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Overall response rate (ORR) to pembrolizumab treatment compared to historical controls. [ Time Frame: 2 years ] | ||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title ICMJE | Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) | ||||
Official Title ICMJE | Phase II Study of Pembrolizumab for PD-L1 Gene-Altered, Relapsed/Refractory DLBCL | ||||
Brief Summary | A non randomized, unblinded, open label phase 2 study to investigate the efficacy of pembrolizumab in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) with PD-L1 genetic alterations | ||||
Detailed Description | Not Provided | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 2 | ||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE | Drug: Pembrolizumab
Subjects will receive pembrolizumab treatment at a dose of 200mg IV every 3 weeks for a duration of 2 years (35 cycles).
Other Name: Keytruda
|
||||
Study Arms ICMJE | Experimental: Pembrolizumab Treatment
Intervention: Drug: Pembrolizumab
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE |
29 | ||||
Original Estimated Enrollment ICMJE | Same as current | ||||
Estimated Study Completion Date ICMJE | August 20, 2024 | ||||
Estimated Primary Completion Date | August 20, 2022 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE |
|
||||
Listed Location Countries ICMJE | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03990961 | ||||
Other Study ID Numbers ICMJE | IRB19-0076 | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE | Not Provided | ||||
Responsible Party | University of Chicago | ||||
Study Sponsor ICMJE | University of Chicago | ||||
Collaborators ICMJE | Merck Sharp & Dohme Corp. | ||||
Investigators ICMJE |
|
||||
PRS Account | University of Chicago | ||||
Verification Date | January 2021 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |